Hycamtin

Primary Peritoneal Carcinosarcoma

Mayo ClinicPhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

14 Active assets in the Primary Peritoneal Carcinosarcoma cohort.

Asset / Sponsor	Phase	Rating
Pembrolizumab Mayo Clinic	Phase 2	B
Cyclophosphamide Mayo Clinic	Phase 2	B
Inno-206 National Cancer Institute (NCI)	Phase 2	B
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Mayo Clinic	Phase 2	B
Irinotecan Roswell Park Cancer Institute	Phase 2	B

View all 16 →

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant

BBB

Indicative ·

74 / 100

cancer of unknown primary siteDormant

BBB

Indicative ·

72 / 100

non-small cell lung carcinomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.